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Summary
Background Substantial reductions in malaria incidence in sub-Saharan Africa have been achieved with massive 
deployment of long-lasting insecticidal nets (LLINs), but pyrethroid resistance threatens control. Burkina Faso is an 
area with intense malaria transmission and highly pyrethroid-resistant vectors. We assessed the effectiveness of 
bednets containing permethrin, a pyrethroid, and pyriproxyfen, an insect growth regulator, versus permethrin-only 
(standard) LLINs against clinical malaria in children younger than 5 years in Banfora, Burkina Faso.
Methods In this two-group, step-wedge, cluster-randomised, controlled, superiority trial, standard LLINs were 
incrementally replaced with LLINs treated with permethrin plus pyriproxyfen (PPF) in 40 rural clusters in Burkina 
Faso. In each cluster, 50 children (aged 6 months to 5 years) were followed up by passive case detection for clinical 
malaria. Cross-sectional surveys were done at the start and the end of the transmission seasons in 2014 and 2015. We 
did monthly collections from indoor light traps to estimate vector densities. Primary endpoints were the incidence of 
clinical malaria, measured by passive case detection, and the entomological inoculation rate. Analyses were adjusted 
for clustering and for month and health centre. This trial is registered as ISRCTN21853394.
Findings 1980 children were enrolled in the cohort in 2014 and 2157 in 2015. At the end of the study, more than 
99% of children slept under a bednet. The incidence of clinical malaria was 2·0 episodes per child-year in the standard 
LLIN group and 1·5 episodes per child-year in the PPF-treated LLIN group (incidence rate ratio 0·88 [95% CI 
0·77–0·99; p=0·04]). The entomological inoculation rate was 85 (95% CI 63–108) infective bites per transmission 
season in the standard LLIN group versus 42 (32–52) infective bites per transmission season in the PPF-treated LLIN 
group (rate ratio 0·49, 95% CI 0·32–0·66; p<0·0001).
Interpretation PPF-treated LLINs provide greater protection against clinical malaria than do standard LLINs and 
could be used as an alternative to standard LLINs in areas with intense transmission of Plasmodium falciparum 
malaria and highly pyrethroid-resistant vectors.
Funding EU Seventh Framework Programme.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Introduction
Malaria control in sub-Saharan Africa has improved 
considerably, with malaria prevalence decreasing by 
roughly 50%, and the incidence of clinical disease 
decreasing by 40%, from 2000 to 2015.1 This reduction 
was achieved largely by massive scaling-up of long-
lasting insecticidal nets (LLINs) and indoor residual 
spraying. Yet, according to WHO,2 the decline in malaria 
incidence and mortality has stalled, and they are even 
increasing in some countries. Burkina Faso, which has 
more than 6 million cases of malaria in children younger 
than 5 years,3 is one of 20 countries in sub-Saharan 
African where malaria cases increased between 2015 and 
2016. It is also one of the few countries with no significant 
association between LLIN ownership and reduction in 
child mortality.4 Although about 90% of households in 
Burkina Faso owned at least one LLIN in 2013,5,6 national 
surveys found that they had little effect on Plasmodium 
falciparum prevalence, with 61% of children aged 
6 months to 5 years infected in 2014.6 One possible 
reason for this ineffectiveness is that malaria parasite 
vectors in Burkina Faso,7 and across most of sub-Saharan 
Africa,8 are becoming increasingly resistant to the 
pyrethroid insecticides used to treat LLINs.
Formulations are under development for treatment 
of LLINs consisting of a pyrethroid in combination 
with another active ingredient, such as pyriproxyfen, to 
increase their effectiveness.9–11 Pyriproxyfen is an insect-
growth regulator recommended for vector control by 
WHO because of its effectiveness at extremely low 
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concentrations, safety in humans,12 and different mode 
of action to other classes of insecticides used for vector 
control. Pyriproxyfen is primarily used as a larvicide, 
preventing metamorphosis of pupae into adults, and can 
be effective for 5–9 months after initial treatment.13,14 It 
can also sterilise adult mosquitoes, or at least reduce 
their fecundity and longevity.15–17
In experimental hut trials, polyethylene nets treated with 
a combination of permethrin and pyriproxyfen (PPF; trade 
name Olyset Duo; Sumitomo Chemical, Tokyo, Japan) 
were associated with increased mortality and reduced 
blood feeding in pyrethroid-resistant Anopheles gambiae 
sensu stricto compared with permethrin-only LLINs 
(trade name Olyset).10,18 Furthermore, PPF-treated LLINs 
sterilised blood-fed mosquitoes that survived exposure to 
pyrethroids.9,18 Similar findings were observed in a pilot 
study11 in which PPF-treated LLINs were introduced into 
village houses in Kenya. We aimed to assess whether PPF-
treated LLINs provide superior protection over permethrin-
only (standard) LLINs against clinical malaria in children 
younger than 5 years in Burkina Faso.
Methods
Study design and participants
A detailed description of the study protocol has been 
reported previously.19 This study was a two-group, step-
wedge, cluster-randomised, controlled, superiority trial 
done in 2014–15 in the southeast of Banfora, Burkina 
Faso, a country where malaria is highly endemic.20 
Resistance to permethrin in the study site was high, with 
discriminating dose assays designed to kill 100% of 
susceptible mosquitoes killing only 13·4–19·2% of 
A gambiae sensu lato in 2014 and 1·0–19·8% in 2015 
(appendix).
Before any study activity, village-level permission was 
sought after sensitisation meetings attended by village 
community leaders and local health staff. Consenting 
villages were grouped into 40 clusters, each consisting of 
one to four neighbouring villages. A census of the study 
villages was done in 2013 to produce a list of all children 
fulfilling the age criteria (age 6 months to 5 years). From 
this list, children were randomly selected for enrolment 
in the cross-sectional survey. We did four cross-sectional 
surveys. The first survey was done at the start of the 
transmission season in June to July, 2014, and defined 
the cohort of children enrolled in the study, with an 
average of 50 children per cluster and roughly equal 
numbers of children aged 6–35 months and 36–60 months. 
A second survey was done at the end of the first year of 
the study in December, 2014, when equal numbers of 
clusters were in each of the study groups. This survey 
included the cohort children and at least an additional 
50 randomly selected children per cluster (stratified by 
age). At the third survey at the beginning of the 
Research in context
Evidence before this study
We searched MEDLINE and the Cochrane Infectious Diseases 
Group Specialized Register using the term “malaria” and one or 
more of the terms “pyriproxyfen”, “combination nets”, 
“long-lasting insecticidal nets”, “insecticide treated nets”, 
“malaria control”, and “vector control” for randomised controlled 
trials, controlled before-and-after intervention studies, and 
interrupted time-series analyses of trials of long-lasting 
insecticidal nets (LLINs) published between Jan 1, 2003, and 
Dec 31, 2017. We restricted our search to 2003 onwards because 
the Cochrane review of insecticide-treated bednets and curtains 
for prevention of malaria covered up to 2003 and did not 
identify any controlled trials comparing pyriproxyfen-treated 
nets with conventional LLINs in control of malaria, nor any trials 
testing mixtures of active ingredients with different modes of 
action. The only trial to test a mixture of chemicals was published 
after our search had been completed and used a net containing 
permethrin and the synergist piperonyl butoxide. The mixture 
net provided better protection against malaria than did 
conventional LLINs. Piperonyl butoxide potentiates the 
insecticidal activity of permethrin, but is not in itself insecticidal 
and cannot fully restore susceptibility of all resistant populations.
Added value of this study
To our knowledge, this clinical trial is the first to assess the 
effectiveness of a bednet treated with pyriproxyfen and of a 
bednet containing a mixture of two active ingredients with 
different modes of action. Use of mixtures of active ingredients is 
considered to be superior to use of single active ingredients for 
management of insecticide-resistant vectors because 
development of resistance to two or more active chemicals with 
different modes of action is likely to be considerably slower than 
for a single active ingredient. We found that the net containing a 
mixture of pyriproxyfen, an insect growth regulator, and 
permethrin, a pyrethroid insecticide, provided better protection 
against clinical malaria in children than did a net treated with only 
permethrin in an area in Burkina Faso where malaria mosquitoes 
are highly resistant to pyrethroids. The new net worked by 
reducing the vector population density and adult lifespan, 
thereby reducing the number of infective bites.
Implications of all the available evidence
Pyrethroid-resistant vectors are now common throughout 
sub-Saharan Africa, making control of malaria with 
pyrethroid-only nets challenging. Nets containing a mixture of 
active ingredients, such as Olyset Duo, provide better protection 
than do conventional pyrethroid-only nets in the prevention of 
clinical malaria in areas of intense transmission of malaria via 
pyrethroid-resistant vectors.
See Online for appendix
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transmission season in May to July, 2015, children who 
had dropped out of the study were replaced, when 
possible, by children of a similar age, and at least 
50 additional randomly selected children per cluster were 
also included. A fourth and final survey was done at the 
end of the study in December, 2015, in the cohort of 
children and in at least an additional 50 randomly 
selected children per cluster.
This study was done in accordance with the principles 
established in the International Conference on 
Harmonisation Tripartite Guideline for Good Clinical 
Practice and the Declaration of Helsinki, whichever 
afforded the greater protection to the participants. The 
trial was approved by the Ethics Committee for Health 
Research, Burkina Faso, on May 13, 2014 (reference 
2014-3-24), and by the School of Biological and Biomedical 
Sciences Ethics Committee, Durham University, UK, on 
Jan 17, 2014. A Data Safety Monitoring Board reviewed 
the trial procedures and results. The only incentives 
given to households that participated in the trial were 
provision of LLINs, treatment of study children during 
the study, and fares to reach referral clinics (refunded by 
study staff on the basis of known tariffs). Written 
informed consent was obtained from each net recipient, 
before net donation and exchange. An additional signed 
informed consent was required from parents or legally 
acceptable representatives of children who participated 
in the clinical assessments.
Randomisation and masking
At the start of the malaria transmission season in June, 
2014, five randomly selected clusters of villages were 
provided with PPF-treated LLINs and the remaining 
35 village clusters with standard LLINs (figures 1 and 2; 
appendix). Five clusters were then randomly selected 
each month from July, 2014, to September, 2014, for 
replacement of standard LLINs with PPF-treated LLINs, 
so that, by the end of 2014, each study group had an 
equal number of clusters (figure 1). In 2015, PPF-treated 
LLINs were deployed in a similar fashion from June to 
September. We used this step-wedge design because it 
represents the type of deployment used by net 
distribution programmes. Random selection was done 
with Stata version 10.
Observer bias was reduced when feasible: both types of 
nets were of similar shape, size, and colour, and blood 
films were read by microscopists masked to the identity 
and intervention status of the participants.
Procedures
White nets (1·8 m wide by  1·9 m long by 1·5 m high) 
containing 2% weight for weight (w/w) permethrin 
incorporated into polyethylene fibres (Olyset Net; 
Sumitomo Chemical) were distributed to achieve one 
LLIN per bed or sleeping place at the beginning of the 
transmission season in 2014. PPF-treated LLINs were the 
same size as standard LLINs and contained 2% w/w 
permethrin and 1% w/w pyriproxyfen incorporated into 
polyethylene fibres (Olyset Duo; Sumitomo Chemical). 
The chemical content of 30 randomly selected LLINs and 
30 PPF-treated LLINs was checked with high-performance 
liquid chromato graphy at the Liverpool School of Tropical 
Medicine (Liverpool, UK), which confirmed the target 
doses (appendix). PPF-treated LLINs were stored and 
distrib uted in a similar manner to the standard LLINs. 
PPF-treated LLINs were exchanged for standard LLINs at 
the household level. Burkina Faso Government’s Roll 
Back Malaria information, education, and communi-
cation procedures were followed to encourage correct net 
use and maintenance for both type of nets.
Passive case detection was used to measure clinical 
malaria incidence in the cohort children, taking into 
account time at risk. Parents or carers of cohort children 
were encouraged to take their child to the nearest local 
health facility if the child was unwell. Clinical malaria 
was defined as a child presenting at a government health 
clinic with an axillary temperature of 37·5°C or higher, or 
a history of fever in the past 48 h, together with the 
presence of P falciparum parasites of any density detected 
by the Paracheck-Pf rapid diagnostic test (RDT; Orchid 
Biomedical Systems, Goa, India) in the absence of other 
detectable causes of fever. To standardise data collection 
in the six health centres, we posted one trained study 
nurse to each facility. These nurses diagnosed malaria 
using RDTs and prepared blood slides that were 
subsequently read at the Centre National de Recherche et 
de Formation sur le Paludisme laboratory in Banfora. 
These nurses also communicated regularly with their 
managers to prevent stock-outs.
To facilitate documentation of all consultations with 
study children, all enrolled children were issued with 
enumerated photo identity cards. A child’s study number, 
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Figure 1: Distribution of interventions throughout the study
PPF=permethrin and pyriproxyfen. LLIN=long-lasting insecticidal net.
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initials, and village code were recorded for all clinical 
events on the case report form. We reimbursed the travel 
costs for patients visiting the health centres to encourage 
uptake of the intervention and reporting to the clinics 
when ill.
We also used anonymised medical records from 
three health facilities located outside of the main study 
area to document clinical malaria based on positive 
RDTs in children aged 6 months to 5 years who lived in 
villages outside of the study area. Although bednets were 
not provided by the study team to this area during 
the study, they were distributed during a nationwide 
bednet distribution campaign in 2014. Data from these 
records allowed tracking of temporal changes in malaria 
incidence in the absence of the intervention, caused by 
factors such as weather patterns. Comparing this trend 
with that in the study area provided additional evidence 
of the scale of community-wide intervention effects.
During the four cross-sectional surveys, all children 
were visited at home and examined clinically for obvious 
symptoms and signs of illness and body temperature. 
Finger-prick samples were collected for haemoglobin 
measurement with a portable spectrophotometer 
(HemoCue version 2.1; HemoCue AB, Ängelholm, 
Sweden) and for thick blood films. Children with fever 
(axillary temperature ≥37·5°C) or fever in the past 48 h 
were tested for malaria with an RDT and, if positive, 
referred to the nearest health facility.
Thick blood films were stained with Giemsa and 
examined under × 1000 magnification. Parasite counts 
were recorded per high-power field, and 100 fields were 
counted before a slide was declared negative. Parasite 
density was estimated assuming that one parasite per 
high-power field was equal to 500 parasites per μL. 
Two slides were prepared from each individual and the 
best slide assessed separately by two experienced 
microscopists, with discrepancies resolved by a third 
microscopist.
We assessed exposure to malaria-vector mosquitoes 
using Centers for Disease Control and Prevention light 
traps every 4 weeks from May, 2014, to December, 2014, 
and from May, 2015, to November, 2015, in six randomly 
selected households from each cluster (figure 2). Light 
traps were positioned next to a single sleeper protected 
with a standard LLIN or a PPF-treated LLIN. Mosquitoes 
were identified by microscopy and the numbers of 
A gambiae sensu lato and other anophelines recorded. 
Sporozoites were detected with an ELISA,21 and a randomly 
selected subset of female A gambiae sensu lato mosquitoes 
were typed to species by PCR.22 Parity of mosquitoes was 
assessed by dissection.
Outcomes
Primary endpoints were the incidence of clinical episodes 
of malaria among cohort children presenting at health 
facilities (clinical primary endpoint) and the ento mological 
inoculation rate (entomological primary endpoint).23 
Secondary endpoints, measured at the end of the 
transmission season in 2014 (when equal numbers of 
clusters were in each of the study groups), were presence 
of malaria parasites, prevalence of high parasi taemia 
(≥5000 parasites per μL), haemoglobin concentration, and 
prevalence of moderate (haemoglobin <80 g/L) or severe 
(haemoglobin <50 g/L) anaemia. Children in the cohort 
were visited at home once a month by project staff for the 
duration of the passive case detection, and if a child was 
absent for more than 50% of a given calendar month then 
their data were censored for that month.
We recorded adverse events and serious adverse events 
in the study cohort and population during the study. The 
trial followed standard definitions for adverse events and 
serious adverse events agreed by consensus of the 
Collaborating Centres of the WHO International Drug 
Monitoring Centre (Uppsala, Sweden). The occurrence 
of adverse events was ascertained by non-directive 
questioning of the study children at monthly visits during 
the trial. Adverse events were also recorded if volunteered 
by study children, parents, or carers, or if noted by 
nurses through physical examination, laboratory tests, or 
other assessments at any contact with the participant. 
2014
Blood sampling Passive case detection
Mosquito trapping PPF-treated LLIN distribution LLIN distribution
January February March April May June July
Rainy season
August September October November December
2015
Figure 2: Timings of interventions and outcome assessment
PPF=permethrin and pyriproxyfen. LLIN=long-lasting insecticidal net.
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Furthermore, we recorded pregnancy outcomes for all 
pregnant women in the study area and asthma signs or 
symptoms in pre-identified residents with asthma.
Statistical analysis
Statistical analyses were done with Stata version 14. For the 
power calculation, we assumed an incidence of clinical 
episodes of malaria of 1·5 episodes per child each year and 
a coefficient of variation of 0·5.19 The study was designed 
to detect a protective efficacy of 25% with PPF-treated 
LLINs compared with standard LLINs, with 90% power 
and at a 5% significance level. For the entomological 
endpoint, the study was 80% powered to detect a 33% 
reduction at a 5% significant level. Methods for sample 
size calculation have been described previously.19
The statistical analysis followed the statistical analysis 
plan written before completion of the trial. The analysis of 
the primary clinical endpoint included all children who 
had a clinical episode of malaria, excluding children who 
had an episode in the month of or after the introduction of 
the intervention. For other outcomes, we excluded data 
from clusters the month of (but not after) the introduction 
of the PPF-treated LLIN. In cases of malaria, further 
attacks of malaria in the 4 weeks after treatment were 
censored because attacks within this period might have 
been false positives resulting from non-malaria fever and a 
positive RDT response due to persistence of parasite 
antigen, and not an active infection.
We calculated the number of clinical episodes, child-
years at risk, and the incidence rate ratio (calculated as the 
ratio of the number of clinical episodes to child-years at 
risk) for each month of the trial in each group, and 
ascertained the intervention effectiveness by subtracting 
the relative rate from the number 1·00. Confidence 
intervals for effectiveness estimates were obtained with 
approximations developed by Bennett and colleagues.24 
We used Poisson regression models with log-transformed 
time at risk as an offset, and with inclusion of village 
cluster as a random effect and calendar month and health 
facility as fixed effects. We considered adjusting for 
potential confounders (age, when participant joined the 
cohort, coverage, and cluster size), and incorporated an 
40 clusters of villages assessed for eligibility
35 clusters (n=1681 children) allocated standard LLINs 5 clusters (n=299 children) allocated PPF-treated LLINs
35 clusters (n=1681 children) 5 clusters (n=299 children)
1980 children in 40 clusters enrolled
Survey 1
(June to July, 2014)
20 clusters (n=887 children) plus 912 additional children 20 clusters (n=908 children) plus 966 additional children
20 clusters (n=910 children) plus 559 additional children 20 clusters (n=1247 children) plus 1389 additional children
Survey 2
(December, 2014)
Survey 3
(May to July, 2015)
0 clusters (n=0 children) 40 clusters (n=2148 children) plus 1952 additional children
Survey 4
(December, 2015)
217 children left
116 aged 6 years
101 lost to follow-up
18 children left
2 aged 6 years
16 lost to follow-up
25 children previously lost 
  to follow-up returned
256 children joined
61 previously lost to
  follow-up returned
195 added
561 children joined
81 previously lost to
  follow-up returned
480 added
151 children lost to 
 follow-up
34 children lost to
follow-up
238 children left
125 aged 6 years
113 lost to follow-up
Figure 3: Trial profile 
The additional children did not form part of the cohort and were, therefore, not included in the passive case detection for the primary endpoint; they were randomly 
selected from the clusters (at least 50 children from each cluster) for inclusion in the surveys (and so contributed to secondary endpoints). Children who had recently 
received PPF-treated LLINs were excluded from some of the analyses. LLIN=long-lasting insecticidal net. PPF=permethrin and pyriproxyfen. *675 children were added 
to the cohort at the third survey to replace those who had exited or were lost to follow-up.  
15
10
15
20
25
30
35
40
45
50
55
Articles
6 www.thelancet.com   Published online August 10, 2018   http://dx.doi.org/10.1016/S0140-6736(18)31711-2
interaction term between study group and calendar month 
to provide month-specific estimates. These findings 
should be interpreted cautiously because interaction tests 
are typically underpowered.25 We explored how changing 
the threshold of parasite density might affect the effect 
estimates of the intervention (appendix).
Secondary endpoints were reported by group with 
means and SDs for continuous outcomes and numbers 
and percentages for categorical outcomes. Continuous 
outcomes were compared between groups with linear 
regression models and categorical outcomes with logistic 
regression models, with village cluster as a random effect 
and health facility as a fixed effect. We repeated the 
analyses stratified by age (<30 months vs ≥30 months; 
defined a priori) and by whether participants were 
included in the original cohort or were added later 
(defined post-hoc).
Numbers of indoor mosquitoes, proportions of 
mosquitoes with sporozoites or that were parous, and 
species composition were summarised by group and 
compared with logistic or negative binomial regression 
models, with inclusion of village cluster as a random 
effect and month and health facility as fixed effects. The 
entomological inoculation rate was defined as the 
number of infective bites received per person during the 
transmission season and was calculated as the household 
density of mosquitoes (estimated as the mean number of 
A gambiae sensu lato per trap each night) multiplied by 
the proportion of mosquitoes with sporozoites and by the 
number of days in the transmission season (n=214 for 
May to November; appendix). We excluded light-trap 
collections for the calendar month that PPF-treated 
LLINs were introduced into a village to allow for a delay 
in the effect of the intervention on the vector population. 
Role of the funding source
The funder of the study and net manufacturers had no 
role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding 
author had full access to all the data in the study and 
had final responsibility for the decision to submit for 
publication.
Results
In 2013, we approached 92 villages in Banfora, Burkina 
Faso, of which 91 agreed to participate in this study after 
community-level meetings to discuss the nature of the 
study and what would be required during the inter-
ventions and investigations. In June, 2014, we distributed 
29 084 LLINs (24 357 standard and 4727 PPF treated) to 
cover the 30 608 sleeping places identified during the 
pre-study population census, yielding an overall coverage 
of 95%. Overall, coverage exceeded 80% in all clusters 
except for one in which residents’ multiple absences 
from home for traditional gold-mining activities made it 
impossible to deliver nets despite numerous attempts 
(appendix).
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Figure 3 illustrates the flow of the cohort children 
through the trial, with some being lost (and some 
returning) and some exiting the study on reaching age 
6 years. At baseline, 1980 children were enrolled into 40 
clusters; the baseline characteristics of these children 
were similar across clusters (grouped by month of rollout 
of PPF-treated LLINs), although there was large variation 
in RDT positivity between clusters (table 1). 675 children 
were added at the third survey to replace those who were 
lost to follow-up or had dropped out of the study; these 
children had largely similar characteristics to those 
already enrolled (appendix). By the fourth survey at the 
end of study, the cohort comprised 2148 children. A 
mean of 46–56 additional children per cluster were 
included in surveys two to four.
The overall incidence of clinical malaria was 1·5 per 
child-year at risk in the PPF-treated LLIN group versus 
2·0 per child-year at risk in the LLIN group (figure 4, 
table 2), corresponding to a crude relative risk of 0·76 
(95% CI 0·71–0·81; table 2). This estimate of the effect 
size is biased because, in both 2014 and 2015, incidence 
was higher in the first part of the transmission season 
(when more children were in the LLIN group) than in the 
September to December period (when more children 
were in the PPF-treated LLIN group; figure 4). Various 
analyses adjusting for calendar month gave lower 
estimates of the reduction in incidence (appendix), with 
the prespecified primary analysis that included adjust-
ment for month and health facility providing evidence of 
a significant difference between the groups (incidence 
rate ratio 0·88, 95% CI 0·77–0·99; p=0·04; table 2). 
Health facility and calendar month were significantly 
associated with clinical incidence (p =0·0001 and 
p<0·0001, respectively), whereas there was no evidence 
of an interaction by month (p=0·97). 
Similar results for the primary endpoint were obtained 
when adjusting for potential confounders (appendix). 
The number of malaria cases reported outside of the 
study area was similar in 2014 and 2015, indicating no 
change in the intensity of malaria transmission between 
the two years (appendix). The use of a more specific case 
definition did not lead to a higher effectiveness estimate 
(appendix).
At the second survey, the proportion of children with 
P falciparum infection was not significantly different 
between the groups (odds ratio [OR] 0·93, 95% CI 
0·74 to 1·15; p=0·50; table 3). High parasitaemia 
(>5000 P falciparum parasites per μL) was non-significantly 
decreased (0·87, 0·73 to 1·02; p=0·09; table 3) and 
haemoglobin concentration was non-significantly 
increased (coefficient 1·8 g/L, 95% CI –0·4 to 3·9; p=0·11; 
table 3) with PPF-treated LLINs compared with standard 
LLINs. However, haemoglobin concen trations were 
significantly increased with PPF-treated LLINs in children 
younger than 30 months (99·3 g/L vs 95·4 g/L for those 
younger than 30 months who received standard LLINs; 
coefficient 3·5 g/L, 95% CI 0·9 to 6·1; p=0·008; appendix). 
The prevalence of moderate anaemia was lower in the 
PPF-treated LLIN group than in the standard LLIN group 
(OR 0·48, 95% CI 0·24–0·96; p=0·04; the difference 
between the groups could not be estimated for severe 
anaemia). The proportion of additional (non-cohort) 
children with high parasitaemia was lower in the PPF-
treated LLINs group than in the standard LLINs group 
(20% vs 24%; 0·80, 0·61–0·96; p=0·02; appendix).
3090 (99%) of the planned 3123 entomological 
collections were successful (houses were locked and 
could not be accessed in the remaining cases). Female 
A gambiae sensu lato were present in 1687 (55%) light-
trap collections (table 4). 45 414 mosquitoes were 
collected, of which 41 548 (91%) were anophelines 
(including 40 587 [98%] that were A gambiae sensu lato) 
and 3866 were culicines. 13 584 A gambiae sensu lato 
mosquitoes were identified at the species level (table 4).
There was no difference in proportions of A gambiae 
sensu stricto and Anopheles coluzzii, the two most 
common vectors, between groups (OR 1·19, 95% CI 
0·94–1·51; p=0·14). Mean proportions of female 
A gambiae sensu lato, parous mosquitoes, and mos-
quitoes with sporozoites were lower in the PPF-treated 
LLIN group than in the standard LLIN group (table 4). 
The entomological inoculation rate was 42 (95% CI 
32–52) infective bites per season in the PPF-treated LLIN 
group versus 85 (63–108) infective bites per season in the 
standard LLIN group (rate ratio 0·49, 95% CI 0·32–0·66; 
p<0·0001; table 4).
The entomological indices were strongly seasonal 
(figure 5), with a wet-season peak in vector densities 
each year and an increase in proportions of parous 
mosquitoes at the end of the wet season. The seasonal 
pattern in proportions of mosquitoes with sporozoites 
differed between 2014 and 2015, and patterns of 
estimated entomological inoculation rates followed 
trends in vector densities. Because of the rollout of 
PPF-nets during the 2 year trial, average values for the 
entomological indices, which were calculated without 
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Figure 4: Effect of PPF-treated LLINs versus standard LLINs on incidence of clinical malaria over time
PPF=permethrin and pyriproxyfen. LLIN=long-lasting insecticidal net.
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accounting for the differential representation over time 
of the two arms of the trial, were similar for standard 
and PPF-treated LLINs (figure 5), despite mosquito 
densities and proportions of mosquitoes that were 
parous or had sporozoites being lower in the PPF-
treated LLIN group than in the standard LLIN group at 
almost all timepoints in the contemporaneous com-
parisons (figure 5). Adjust ment for the differential 
contributions at different time periods was important 
in providing coherent estimates of the effect of the 
inter vention on overall entomological outcomes 
(table 4).
There were 21 non-serious adverse events in the 
standard LLIN group and one in the PPF-treated LLIN 
group (appendix). Adverse events were mostly mild, 
although eight, all in the standard LLIN group, were of 
moderate severity. Only six adverse events (five in the 
standard LLIN group and one in the PPF-treated LLIN 
Number of malaria episodes 
reported
Years of exposure Incidence of clinical malaria 
(per child-year at risk) 
% reduction Rate ratio 
(95% CI)
Model-based rate ratio 
(95% CI)*
Standard LLINs PPF-treated 
LLINs
Standard LLINs PPF-treated 
LLINs
Standard LLINs PPF-treated 
LLINs
June, 2014 33 ·· 79 ·· 0·4 ·· ·· ·· ··
July, 2014 454 ·· 123 ·· 3·7 ·· ·· ·· ··
August, 2014 244 43 103 23 2·4 1·9 22% 0·78 (0·54–1·13) 0·83 (0·59–1·17)
September, 2014 177 66 79 39 2·3 1·7 25% 0·75 (0·55–1·01) 0·82 (0·60–1·10)
October, 2014 212 155 81 63 2·6 2·5 7% 0·93 (0·75–1·16) 0·93 (0·74–1·16)
November, 2014 193 170 78 81 2·5 2·1 16% 0·84 (0·68–1·05) 0·90 (0·72–1·12)
December, 2014 111 92 80 84 1·4 1·1 20% 0·80 (0·59–1·07) 0·85 (0·63–1·13)
May, 2015 15 14 789 82 0·2 0·2 10% 0·90 (0·42–1·94) 0·95 (0·46–1·99)
June, 2015 42 50 59 77 0·7 0·6 9% 0·91 (0·59–1·41) 0·91 (0·60–1·38)
July, 2015 146 223 54 99 2·7 2·3 17% 0·83 (0·66–1·04) 0·79 (0·63–1·00)
August, 2015 64 266 29 123 2·2 2·2 1% 0·99 (0·73–1·34) 0·98 (0·73–1·32)
September, 2015 ·· 271 ·· 139 ·· 1·9 ·· ·· ··
October, 2015 ·· 337 ·· 166 ·· 2·0 ·· ·· ··
November, 2015 ·· 304 ·· 185 ·· 1·6 ·· ·· ··
December, 2015 ·· 56 ·· 189 ·· 0·3 ·· ·· ··
Total 1691 2047 844 1351 2·0 1·5 24% 0·76 (0·71–0·81) 0·88 (0·77–0·99); p=0·04
LLIN=long-lasting insecticidal net. PPF=permethrin and pyriproxyfen. *Poisson model with offset for exposure time (natural log transformed), a random intercept for cluster, month, and health facility as fixed 
effects, and an interaction term between month and study group to obtain month-specific estimates.
Table 2: Incidence of clinical malaria in the cohort
Survey 1 Survey 2 Survey 3 Survey 4
Standard LLINs 
(n=1681)
PPF-treated 
LLINs (n=0)
Standard LLINs 
(n=1799)
PPF-treated LLINs 
(n=1874)
Standard LLINs 
(n=1469)
PPF-treated LLINs 
(n=1984)
Standard 
LLINs (n=0)
PPF-treated LLINs 
(n=4100)
Sex
Girls 829 (49%) ·· 903 (50%) 923 (49%) 713 (49%) 958 (48%) ·· 2004 (49%)
Boys 852 (51% ·· 896 (50%) 951 (51%) 756 (51%) 1026 (52%) ·· 2096 (51%)
Age (months) 35 (15·0) ·· 41 (15·0) 41 (15·2) 38 (13·6) 37 (14·0) ·· 43 (14·4)
Sleeps under a mosquito net 1549/1681 (92%) ·· 1793/1799 (>99%) 1867/1874 (>99%) 1411/1423 (99%) 1901/1910 (>99%) ·· 3909/3913 (>99%)
Presence of Plasmodium 
falciparum parasites by 
microscopy*
851/1627 (52%) ·· 1096/1761 (62%) 1124/1843 (61%) 604/1388 (44%) 757/1854 (41%) ·· 2159/3758 (57%)
>5000 P falciparum per μL* 229/1627 (14%) ·· 358/1761 (20%) 338/1843 (18%) 172/1388 (12%) 208/1854 (11%) ·· 627/3758 (17%)
Haemoglobin (g/L)* 101·5 (13·5) ·· 101·4 (13·9) 103·5 (11·7) 104·3 (12·4) 105·5 (11·6) ·· 103·7 (10·7)
Moderate anaemia*† 104/1511 (7%) ·· 113/1768 (6%) 54/1782 (3%) 62/1420 (4%) 51/1834 (3%) ·· 62/3726 (2%)
Severe anaemia*‡ 2/1511 (<1%) ·· 7/1768 (<1%) 0 1/1420 (<1%) 0 ·· 0
Data are n (%), mean (SD), or n/N (%). Survey 1 was done in June, 2014, to July, 2014; survey 2 in December, 2014; survey 3 in May, 2015, to July, 2015; and survey 4 in December, 2015. Includes cohort and 
additional children, but excludes children during the month of and after distribution of the intervention; thus, the number of children in the first survey differs from those in table 1. LLIN=long-lasting insecticidal 
net. PPF=permethrin and pyriproxyfen. *Secondary endpoint; assessed at survey 2 when the number of clusters in each study arm was equal.  †Defined as <80 g/L. ‡Defined as <50 g/L.
Table 3: Characteristics of children at the cross-sectional surveys, by group
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group) were related to the study. All adverse events were 
resolved after treatment or over time. 19 serious adverse 
events occurred (ten in the standard LLIN group and nine 
in the PPF-treated LLIN group), of which 13 resulted in 
hospital admission and six in death; none were related to 
the study. There were no indications of any serious 
adverse events associated with the PPF-treated LLINs.
Discussion
In a rural area of Burkina Faso with high bednet coverage, 
high levels of malaria transmission, and the presence of 
vectors highly resistant to permethrin, we found that 
children sleeping under PPF-treated LLINs were 12% less 
likely to have clinical malaria and 52% less likely to have 
moderate anaemia than were those sleeping under 
standard LLINs. The power calculation for the primary 
endpoint was conservative and based on assumed rates of 
malaria transmission that were considerably lower than 
found during the trial. The absolute reduction in clinical 
incidence was similar to that for which the trial was 
powered, but the effect size was only 12% (compared with 
25% in the power calculations) because the control 
incidence was higher than anticipated. Clinical incidence 
saturates with transmission rate, so a 49% reduction in the 
EIR translates into a lower effect on clinical incidence at a 
high background EIR. The reduction in moderate anaemia 
is clinically relevant because anaemia due to malaria is a 
major cause of mortality in children younger than 2 years.26 
The entomological data suggest that protection arose 
from the mass killing of malaria vectors, reducing the 
density of the vector population, and support evidence of 
a protective effect for PPF-treated LLINs. In clusters 
provided with PPF-treated LLINs, vector numbers were 
reduced by 22% and the odds of finding parous (older) 
mosquitoes by 31%, consistent with the anticipated mass 
effect of this intervention. The reduction in vector 
numbers and fewer older mosquitoes resulted in a 51% 
reduction in the entomological inoculation rate in the 
PPF-treated LLIN group.
There was no measurable effect of PPF-treated LLINs 
on malaria parasite prevalence, which was consistent with 
other studies that showed that prevalence is only weakly 
associated with entomological inoculation rate in the 
observed range of roughly 40–80 infective bites per year in 
unprotected individuals.27 The high parasite prevalence of 
around 60% diagnosed by microscopy, despite levels of 
bednet ownership being much higher than reported for 
most countries,2 probably means that nearly every child in 
the study area is infected with parasites.28 Presumably, 
most children were harbouring infections that had 
persisted since before the trial and which, therefore, could 
not have been averted by the new nets. This high 
prevalence also led to a downward bias in the estimate of 
effectiveness against clinical malaria because the numbers 
of clinical malaria cases recorded in both groups of the 
trial were inflated by cases of fever resulting from non-
malarial causes but diagnosed as malaria because of 
incidental parasitaemia, suggesting that the true efficacy 
against disease is likely to be higher than 12% (appendix).
The mode of action of the PPF-treated LLIN is complex 
because it relies on a combination of factors: an intact 
bednet correctly used provides a physical barrier against 
blood-seeking mosquitoes, the permethrin on the net has 
excito-repellent properties that result in rapid knock down 
and death of pyrethroid-susceptible mosquitoes, and 
pyriproxyfen reduces both adult longevity and 
reproductive outputs of female mosquitoes. Although the 
permethrin concentration on the two net types was the 
Unadjusted estimates Adjusted estimates*
Standard LLINs PPF-treated LLINs Standard LLINs PPF-treated LLINs Effect estimate p value
Light-trap collections 1248 1842 ·· ·· ·· ··
Mosquitoes collected 16 785 28 629 ·· ·· ·· ··
Female Anopheles gambiae sensu lato collected 14 489 (86%) 25 820 (90%) ·· ·· ·· ··
Species composition of A gambiae sensu lato†
Anopheles arabiensis 56/4774 (1%) 148/8810 (2%) ·· ·· ·· ··
Anopheles coluzzii 403/4774 (8%) 1116/8810 (13%) ·· ·· ·· ··
A coluzzii and A gambiae sensu stricto hybrids 5/4774 (<1%) 4/8810 (<1%) ·· ·· ·· ··
A gambiae sensu stricto 4310/4774 (90%) 7542/8810 (86%) ·· ·· ·· ··
A coluzzii‡ 403/4713 (9%) 1116/8658 (13%) ·· ·· OR 1·19 (0·94–1·51) p=0·14
Female A gambiae sensu lato collected per trap§ 12 (32) 14 (36) 9·4 (7·7–11·0) 7·3 (6·1–8·5) RR 0·78 (0·68–0·89) p=0·0002
Proportion of parous mosquitoes 60% (625/1038) 62% (1364/2198) 69% (64–74) 61% (57–65) OR 0·69 (0·52–0·91) p=0·009
Proportion of mosquitoes with sporozoites¶ 4% (206/4858) 3% (273/8935) 4·3% (3·4–5·1) 2·7% (2·3–3·1) OR 0·62 (0·47–0·83) p=0·001
Estimated EIR (infective bites per transmission 
season)
·· ·· 85 (63–108) 42 (32–52) RR 0·49 (0·32–0·66) p<0·0001
Data are n, n (%), or % (n/N), unless otherwise specified. LLIN=long-lasting insecticidal net. PPF=permethrin and pyriproxyfen. OR=odds ratio. RR=rate ratio. EIR=entomological inoculation rate. *Models included 
cluster as a random effect and month and health facility as fixed effects; numbers in parentheses are 95% CIs. †Typing to species level was missing for 85 mosquitoes in the standard LLIN group and 126 in the PPF-
treated LLIN group. ‡Data are A coluzzii as a proportion of A coluzzii (n=403) plus A gambiae sensu stricto (n=4310). §Data are mean (SD). ¶ Missing for one mosquito in the PPF-treated LLIN group. 
Table 4: Entomological results
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same, the bleed rates (the rate at which permethrin leaks 
from the fibres onto the surface of the netting) were 
greater in the PPF-treated than in the standard LLINs. 
This higher bleed rate meant that the surface 
concentration of permethrin was probably higher on the 
PPF-treated LLINs than on the standard LLINs. This 
hypothesis is supported by studies10,18,29 that have found 
that mortality is higher in pyrethroid-resistant mosquitoes 
exposed to PPF-treated LLINs than in those exposed to 
conventional LLINs. Another cluster-randomised trial30 is 
ongoing in the same district to compare the durability of 
PPF-treated LLINs and standard LLINs. The results of 
that trial might enable disentangling of the factor(s) that 
account for the superior protection provided by PPF-
treated LLINs. At present, we cannot be certain whether 
the protective effect is due to increased concentrations of 
permethrin on the fibre, PPF, or both.
Few opportunities exist to manage insecticide resistance 
in Anopheles mosquitoes in sub-Saharan Africa, where 
pyrethroid-treated LLINs are often the only tool for 
malaria prevention. Nets treated with mixtures of active 
chemicals, such as Olyset Duo, are an advancement on 
pyrethroid-only nets, providing that they are cost-effective 
and there is no cross-resistance between the two chemical 
classes. Evidence suggests that the elevated concentrations 
of cytochrome P450s in pyrethroid-resistant Anopheles 
populations might reduce the bioefficacy of pyriproxyfen.29 
Thus, the exceptionally high levels of permethrin 
resistance in the study site might reduce the effectiveness 
of both components of the PPF, and the effectiveness of 
PPF-treated LLINs might be greater in areas with lower 
levels of pyrethroid resistance and vectorial capacity. 
Future studies should test, in areas of high pyrethroid 
resistance, nets treated with mixtures of active ingredients 
that have different modes of action and which do not 
include pyrethroids.
This study has two main limitations. First, although the 
communities were masked to the interventions, it is 
possible that study participants would view a new net as 
better than an old one, potentially resulting in under-
reporting of clinical cases in the PPF-treated LLIN group. 
Second, the large-scale use of PPF-treated LLINs might 
have reduced the number of malaria vectors dispersing 
from these clusters into adjacent clusters with stand-
ard LLINs, and this edge effect will be explored in a 
future analysis. 
The rapid spread of pyrethroid resistance in African 
vectors is a cause of concern. Although direct evidence 
that this spread of resistance is interfering with malaria 
control is lacking, it is likely that it will become a problem 
in the future. The only strong indication that resistance is 
interfering with malaria control comes from a two-group 
trial31 of pyrethroid nets, which found that addition of 
piperonyl butoxide to the nets improved protection 
against clinical malaria.31 Piperonyl butoxide is a synergist 
that potentiates the insecticidal activity of permethrin, 
but cannot fully restore susceptibility in all resistant 
populations. Therefore, alternative strategies for dealing 
with insecticide resistance are urgently needed. We 
selected Olyset Duo as the most commercially advanced, 
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dual-action mixture net and did the trial in one of the 
most challenging settings in sub-Saharan Africa, where 
pyrethroid resistance in vectors is high and extremely 
common, and vectorial capacity is one of the highest in 
the region. We found that substantial numbers of malaria 
cases in children could be averted by these nets in such 
areas. In Burkina Faso, 6 014 021 uncomplicated malaria 
cases in children younger than 5 years were rec-
orded in 2017;3 thus, a 12% reduction in malaria incidence 
due to use of PPF-treated LLINs would equate to 
721 683 cases averted.
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